Sucralfate Pellets

(Product under development)
Sucralfate PelletsSucralfate is a cytoprotective agent, an oral gastrointestinal medication primarily indicated for the treatment of active duodenal ulcers.

Brand names include Sucramal in Italy; Carafate in U.S.A.; Pepsigard, Sucral, Sucrafil, Hapifate in India; Sutra in parts of South-East Asia; Sulcrate in Canada; Ulsanic in South Africa; and Antepsin in Turkey. Sucralfate is also used for the treatment of gastroesophageal reflux disease (GERD) and stress ulcers.

Unlike the other classes of medications used for treatment of peptic ulcers, sucralfate is a sucrose sulfate-aluminium complex that binds to the mucosa, thus creating a physical barrier that impairs diffusion of hydrochloric acid in the gastrointestinal tract and prevents degradation of mucus by acid.

It also stimulates bicarbonate output and acts like an acid buffer with cytoprotective properties. Sucralfate was approved by the U.S. Food and Drug Administration (FDA) in 1981.

Available Form:
Sucralfate Pellets
Sucralfate Granules

Umang Pharmatech equipments used for production of Sucralfate Pellets:
Drug Layering, Fluid Bed Dryer, Fluid Bed Coater, Sifter & Blender, Extruder and Twin spheronizer.

Sucralfate Pellets
Systematic (IUPAC) Name
Sucralfate Pellets
Sucralfate Pellets
Chemical data
Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum
CAS number : 54182-58-0
ATC code : A02BX02
PubChem : CID 6398525
DrugBank : APRD01238
ChemSpider : 4911161
UNII : XX73205DH5
Formula : C12H54Al16O75S8
Mol. mass : 2086.75 g/mol

* All transactions are carried out in conformity with patent laws applicable in the user country. Active pharmaceutical ingredients or formulations thereof will not be supplied in countries where the same is under patent protection except as and if permitted under law of the country for research and development purposes only.
Extruder Spheronizer Email Us Umang Pharmatech